Corporation
Gilead Sciences Canada
- Meetings this Parliament
- 47
- With MPs
- 12
- Since Nov 2021
- 107
- Active registrations
- 1
Most recent reported meeting: Sep 22, 2026.
Lobbying by Gilead Sciences Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Apr 2, 2026
Filed by Paul Petrelli, General Manager
Lobbyists
- Bobby Sutherland · Sr. Director, Government Affairs
- Paul Petrelli · General Manager
Institutions they may lobby: CUSMA Secretariat, Canadian Institutes of Health Research (CIHR), Correctional Service of Canada (CSC), Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (9)Hide details
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
- Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
- Free Trade agreements as they relate to the biopharmaceutical industry
- Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
- Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
- Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
- Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Registration 959600-360912-19. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Paul Petrelli (50), Christophe Griolet (39), Scott Spencer (9), Melissa Koomey (9).
-
Reported by Christophe Griolet · In-house (corporation)
- Eshan Naik · Director of Policy, House of Commons
- Jean-Sebastien Bock · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
Economic DevelopmentHealthIndustryResearch and Development
-
Reported by Christophe Griolet · In-house (corporation)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
Economic DevelopmentHealthIndustryInternational TradeResearch and Development
-
Reported by Christophe Griolet · In-house (corporation)
- Jennifer Miller · Assistant Secretary to Cabinet, Social Development Policy Branch, Privy Council Office (PCO)
Economic DevelopmentHealthResearch and Development
-
Reported by Christophe Griolet · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
HealthResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
- Wilder Walker-Stewart · Policy Advisor, Health Canada (HC)
Aboriginal AffairsHealthScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Mike Burton · Chief of staff, Immigration, Refugees and Citizenship Canada (IRCC)
Federal-Provincial RelationsHealth
-
Reported by Christophe Griolet · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
- René Cormier · Senator, Senate of Canada
Health
-
Reported by Christophe Griolet · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
HealthResearch and Development
-
Reported by Christophe Griolet · In-house (corporation)
- René Cormier · Senator, Senate of Canada
HealthResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
HealthResearch and Development
-
Reported by Christophe Griolet · In-house (corporation)
- Bianca Hossain · Policy Head, Life Sciences, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- David Boudreau · Director General, Health Canada (HC)
HealthScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Ed Morgan · Director General, Policy, Health Canada (HC)
HealthResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Jocelyne Voisin · ADM, Strategic Policy Branch, Health Canada (HC)
HealthResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Michelle Boudreau · Executive Director, Health Canada (HC)
HealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Economic DevelopmentHealthResearch and Development
-
Reported by Christophe Griolet · In-house (corporation)
- Jordan Ames-Sinclair · Special Assistant, Policy, Health Canada (HC)
HealthResearch and Development
-
Reported by Christophe Griolet · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
- Allison Haley · Director of Parliamentary Affairs, House of Commons
Economic DevelopmentHealthResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Jean-Yves Duclos · Minister of Health, Health Canada (HC)
- Jordan Ames-Sinclair · Special Assistant, Policy, Health Canada (HC)
- Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
Economic DevelopmentHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Eric Costen · Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Eric Costen · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
- Benoit Leduc · Manager, Innovation, Science and Economic Development Canada (ISED)
- Caroline Menard · Manager, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Christophe Griolet · In-house (corporation)
- Jordan Ames-Sinclair · Special Assistant, Policy, Health Canada (HC)
HealthResearch and Development
-
Reported by Melissa Koomey · In-house (corporation)
- Randy Boissonnault · Minister of Tourism and Associate Minister of Finance, Innovation, Science and Economic Development Canada (ISED)
HealthIndustryInternational TradeResearch and DevelopmentScience and Technology
-
Reported by Melissa Koomey · In-house (corporation)
- Jean-Yves Duclos · Minister of Health, Health Canada (HC)
- Jordan Ames-Sinclair · Director of Policy and Stakeholder Relations, Health Canada (HC)
HealthResearch and DevelopmentScience and Technology
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.